HC Wainwright & Co. Maintains Buy on Mind Medicine, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Mind Medicine (NASDAQ:MNMD) and increased the price target from $35 to $55, indicating a positive outlook for the company's stock.
August 29, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Mind Medicine and increased the price target from $35 to $55, suggesting a positive outlook for the stock.
The increase in the price target from $35 to $55 by HC Wainwright & Co. indicates a strong positive sentiment from the analyst, which is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100